Key Points
- Daniel Patrick O'Day sold 115,640 Gilead shares on Jan. 23 at an average of $135 for proceeds of $15,611,400, cutting his stake by 16.95% to 566,698 shares (≈$76.5M), per an SEC filing.
- The Jan. sale follows three prior monthly dispositions (10,000 shares each in Oct., Nov. and Dec.), totaling 145,640 shares sold for about $19.32M, even as analysts keep a Moderate Buy consensus and Gilead guides FY2025 EPS of 8.05–8.25.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 115,640 shares of the company's stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Daniel Patrick O'day also recently made the following trade(s):
- On Monday, December 29th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00.
- On Friday, November 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00.
- On Tuesday, October 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00.
Gilead Sciences Price Performance
NASDAQ GILD opened at $137.78 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $170.94 billion, a PE ratio of 21.36, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. Gilead Sciences, Inc. has a 12-month low of $93.10 and a 12-month high of $138.03. The company has a 50 day moving average price of $124.25 and a two-hundred day moving average price of $118.88.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. Gilead Sciences's quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Wells Fargo & Company increased their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, December 10th. Needham & Company LLC increased their price target on Gilead Sciences from $133.00 to $140.00 and gave the company a "buy" rating in a report on Thursday, November 13th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a research note on Friday, October 31st. Finally, Mizuho upped their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an "outperform" rating in a report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $134.52.
View Our Latest Stock Analysis on GILD
Institutional Investors Weigh In On Gilead Sciences
A number of institutional investors have recently added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Financial Consulate Inc. boosted its stake in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 109 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences in the second quarter valued at $27,000. Finally, BOCHK Asset Management Ltd acquired a new position in Gilead Sciences during the fourth quarter worth $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
